Expert Interview
Discussing the potential of Novartis' gene therapy, Zolgensma (onasemnogene abeparvovec) in spinal muscular atrophy and the data for the LTFU studies
Ticker(s): NVSInstitution: Children's Hospital of Richmond (at VCU)
- Assistant Professor, Division of Child Neurology at VCU & Dual-board certified child neurologist and neuromuscular physician.
- Currently treats 60 to 70 patients with DMD.
- Clinical and research interests are in pediatric neuromuscular disorders with a particular focus on Duchenne Muscular Dystrophy; has served as the PI of several clinical trials in DMD and site investigator for Exon 51.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
